Home › NCT07131592

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

The Effect of Tranexamic Acid on Drainage Volume and Time to Drain Removal in Reduction Mammaplasty Patients

Who can join

Ages 18 and older · Women

Inclusion Criteria:

* Adults aged 18 years or older
* Elective bilateral breast reduction
* Patient understands and is willing to participate in the study
* Patient willing to and capable of providing informed consent

Exclusion Criteria:

* Age less than 18 years old
* Prior radiation to the breast
* Secondary/Revision breast reduction
* Known coagulopathy or bleeding disorders
* Intraoperative coagulopathy
* History of seizures
* Active smokers
* Allergy or contraindication to TXA
* Pregnant or breastfeeding patients
* Patient is unable or unwilling to complete the anticipated study follow-up
* Inability to understand the aims and objectives of the study
* Inability to or unwilling to provide informed consent

About the study

This study aims to evaluate whether tranexamic acid (TXA), a medication that helps reduce bleeding, can decrease fluid drainage after breast reduction surgery. Participants will be randomly assigned to receive either intravenous TXA or no TXA during surgery. Additionally, one breast will receive TXA through the surgical drain, while the other will receive saline. This approach allows to compare the effects of TXA on fluid buildup and healing. The goal is to improve recovery and reduce complications after breast reduction surgery.

What is being tested

• IV TXA (drug)
• Topical TXA (drug)
• Topical saline (drug)

Sponsor: Massachusetts General Hospital · Participants: 160 · Started: Nov 18, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07131592

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.